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Nanotechnologies have reached a level of maturity and market penetration that require nano-specific 
changes in legislation and harmonization among legislation domains, such as the amendments to 
REACH for nanomaterials (NMs) which came into force in January 2020. Thus, it is timely to 
undertake an assessment of the components and regulatory boundaries of  NMs risk governance, 
alongside related methods and tools, as part of the global efforts to optimise nanosafety and integrate it 
into product design processes, via Safe(r)-by-Design (SbD) concepts. This paper provides an overview 
of the state-of-the-art regarding risk governance of NMs and lays out the theoretical basis for the 
development and implementation of an effective, trustworthy, transparent and practical risk governance 
framework for NMs. The proposed framework enables a continuous integration of the evolving state of 
the science, leverages best practice from contiguous disciplines and facilitates responsive re-thinking of 
nanosafety governance to meet future needs. To achieve and operationalise such a framework, a 
dedicated, science-based Risk Governance Council (RGC) for NMs is currently being developed. The 
framework will provide a toolkit for independent NMs’ risk governance and integrates the needs and 
views of all stakeholders. An extension of this framework to other relevant advanced materials and 




The rapid expansion of nanotechnology as a key enabling technology (KET) in several economic 
sectors raises significant concerns in the scientific and regulatory world in many European countries, 
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health (both workers and consumers) and the environment[1], while the concerns of the public are 
highly dependable on the risk perception of NMs and the level of understanding of 
nanotechnology.[2]–[5] Such concerns, if not governed by proper risk assessment and management 
approaches, may significantly hamper the great potential of nanotechnology to deliver industrial, 
energy, environmental, health and other benefits.[6] In general, the rapid development of 
nanotechnologies has not been matched by the speed of nano-specific adjustments in regulatory 
frameworks for safety management.[7] NMs are already accepted as vital for new technologies and 
innovation, as evidenced by the existence of the EU Observatory for Nanomaterials[8] and the 
National Nanotechnology Initiative of the USA[9], however, the increasing rate of their utilisation 
seems to outpace regulators and researchers in adjusting regulation and research, leaving a gap 
regarding proper handling of NM-related environmental and human health risks.[10]–[12] This 
consideration of a regulatory gap, whether real or perceived, demonstrates a need to reassess 
already adopted NMs, especially those commonly produced and used across a range of applications, 
as well as emerging innovative NMs, which is where risk governance comes to the fore.[13] In order to 
appropriately manage and support innovation, commercial and regulatory decisions must be clearly 
guided by a broad set of civil society interests and should be supported by clear, reliable, relevant 
and understandable scientific outputs and data, which must also be legally sound and defensible.[14] 
 
Governance systems aim to provide all actors with clarity and defined rules to understand what 
forms of behaviour are acceptable and valid, as well as which actions and behaviours are outside the 
boundaries of established best practices, codes of conduct, and overall operating procedures. [15]–[18] 
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international development through its use by the International Monetary Fund, World Bank and 
other bodies,[19] ‘what ‘good governance’ entails’ is a persistent debate as best practices attempt to 
keep pace with contemporary socio-economic developments,[20] especially at the axis of risk and 
innovation.[21] Different forms of governance have varying compositions of principles and practices, 
such as the values and operating practices of prominent governing bodies of a certain area. These 
principles and practices are informed by trade-offs in risks and benefits, or, in other words, 
governance weighs the potential gains and externalities that may be accrued should an activity or 
product be allowed to enter into the public domain or commercial marketplace.[22] The trade-offs are 
particularly salient for technology development and commodification,[23] where developers’ 
economic and scientific incentives must be balanced against the potential health hazards and 
security implications posed by a specific technology. This balance is a fundamental challenge of risk 
governance, where the perspectives, incentives, and needs of various stakeholders and interest 
groups inform the regulatory requirements and/or informal procedures needed for governing the 
development pathway and commercialisation of a new technology to enter the marketplace. The 
International Risk Governance Council (IRGC) was first to address the risk governance of emerging 
and systemic risks, as a response to policy challenges, and developed a generic framework for risk 
governance, which has been considered broadly applicable for nanotechnology as an emerging 
technology.[24], [25] 
Despite the significant progress achieved in risk evaluation, risk assessment and risk management, of 
NMs, there is still an urgent need to implement a robust and reliable methodology for risk 
governance of NMs via benchmarked decision-making tools. Within the EU H2020 program, the 
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through joint efforts from three projects (Gov4Nano[26], NANORIGO[27] and RiskGONE[28]) has been 
initiated. The RGC development is founded on a clear understanding of risks, risk management 
practices and the societal risk perception by all stakeholders to allow the EU member states to fully 
exploit the economic and social potential of NMs and nanotechnologies broadly. 
 
2. Governance of emerging technologies 
Governance of technologies, in more established and better understood fields, is largely informed by 
economic, social and environmental considerations. Technologies in these fields often represent an 
incremental, as opposed to radical, change, and therefore many of the mechanisms are likely to 
have already been established, where regulators and other actors have kept pace with the 
development of a given technology. Within emerging technologies, corresponding innovation could 
be deemed radical or disruptive, which is often accompanied by a set of new and unique governance 
challenges arising from reduced understanding of the health and environmental impacts of the new 
technology. The governance challenges posed by NMs, include a range of ethical, social, political and 
technical issues, such as their dynamic nature, specific physico-chemical properties (both intrinsic 
and extrinsic depending on context and surroundings), ageing, environmental transformations, 
behavior, features and effects.[29]–[32] 
Governance is largely informed by the joint actions of risk analysis (including measures of risk 
prevention, mitigation, or transfer) and risk communication. Assuming that the properties of a 
technology and technological outcomes are well-understood and scientifically testable, such 
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potential hazards, magnitude of exposure and exposure pathways, i.e., potential exposure of 
workers or consumers, environmental fate and transport, etc. Using various tests and benchmarks, 
the potential hazards of the technology and its products are reviewed along their life cycle against 
potential risks, including the magnitude and the frequency of occurrence of such risks. Based on 
such reviews, the technologies and products are refined and improved to be compliant with formal 
regulation or less formal ‘soft laws’, i.e., industrial standards and best practices, before entering the 
market.[33] Efforts on risk communication with stakeholders and the lay public are commendable to 
(a) inform the public regarding the safe use procedures for the given product, (b) field any potential 
concerns that may not have been reflected in testing, and (c) communicate with the public regarding 
the absence of specific risks after rigorous hazard testing and evaluation (assuming that this is 
backed by the experimental data acquired). 
Emerging technologies pose unique issues to the whole governance process, in ways that 
conventional materials or products generally do not.[17] Notably, emerging technologies like 
nanotechnology might possess unique, uncertain, or incompletely characterized features such as 
their dynamic evolution. Given their emerging nature and current knowledge gaps, hazards 
associated with NMs may be difficult to quantify,[34], [35] while robust exposure assessment needed 
for a proper risk assessment is still an issue.[36] Particularly, risk analysis of NMs suffers from a lack of 
widely applicable testing strategies and assessment benchmarks, which essentially render any risk-
based nanotechnology governance strategy as contested and unable to inform safe operating 
procedures.  Uncertainty related to physicochemical properties may alter the assessment of hazards 
and risks even for traditional materials, thus the impact of compounding uncertainties for NMs may 
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For example, European Chemicals Agency (ECHA) has recently introduced the concept of nanoforms 
and groups of nanoforms that are sufficiently similar as to have the same toxicity, however the 
boundaries of these sets of nanoforms have yet to be established. Currently, we do not have a clear 
understanding of whether a 50nm TiO2 NM with 80:20 anatase:rutile is the same as a 50 nm TiO2 NM 
with 75:25 anatase: rutile in terms of biological effects, nor whether a 40 ± 5 nm and a 50 ± 10 nm 
NM of the same composition are sufficiently similar in terms of their uptake and hazard to constitute 
a set of nanoforms. 
Without having a clear understanding of the issues described above, it is politically and 
institutionally difficult to craft and enforce standards for the broader technology development and 
policymaking communities.[6], [37] Existing consensus processes to develop and validate agreed 
standardised testing strategies and guidance documents are slow and unwieldy, [14] even where 
strong political will exists, such as the OECD (Organisation for Economic Co-operation and 
Development) activities and the ‘Malta Initiative’.[38]–[41] 
Given these difficulties and the lack of a reliable, scientifically-based and clear testing strategy for 
risk assessment of NMs, scholars have called for the urgent and timely use of risk governance.[6], [42], 
[43] The International Risk Governance Council (IRGC) characterises risk governance into discrete 
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5) communication of risk within a specific context that is influenced by the interactions 
and preferences of various stakeholders.
[21]
 
NMs represent an accumulation of incremental innovations, leading to a larger, more radical step 
which has driven the rapid development and commercialisation of certain NMs. Despite their 
prevalence already in the human environment, NMs can still be considered an emerging technology 
(defined as a technology reaching their potential within 3-5 years), given the insufficient maturity of 
societal understanding of the risks and benefits of NMs and how this understanding is conveyed to 
stakeholders, the radical novelty, rapid growth, variety of potential NMs composition, and their 
prominent impacts where applied in comparison to the status quo.[44] In short, the full impact of 
NMs is not yet fully understood unlike many larger scale chemical equivalents. In the research and 
development phases for NMs there are ranges of governance regimes, at firm or institution level, 
which determine what and how NM innovations are, or are not developed. These more ‘local’ 
governance systems are also influenced by larger systems, such as regional or national regulatory 
frameworks. 
Harmonisation across regulatory frameworks and domains, even within a single country, is 
challenging.  For example, US chemical safety regulation (TSCA) allows registration of a NM for a 
specific use (as per drug approvals for a specific disease endpoint), while the EU’s chemical 
legislation, REACH (Registration, Evaluation, Authorisation and Restriction of Chemicals), requires 
registrants to consider all possible utilisation / exposure scenarios, which therefore establishes firm 
requirements and criteria to be fulfilled before a NM for the specified applications can enter the EU 
market. This places the burden upon firms wishing to commercialise NMs to demonstrate the safety 
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for small businesses. A requirement to consider all use scenarios for a new material as a basis for 
regulation will inevitably leave gaps, while also placing a burden on businesses to explore uses 
beyond their targeted markets and applications. 
An important challenge for NMs risk governance (and indeed commercialisation) is that the same 
NM may have multiple different applications, each of which has a completely different exposure 
route, exposure form, exposure potential, potential risk and possibly life cycle. For example, silver-
based NMs are widely used in inkjet printing but also as antibacterial agents in wound dressings and 
medical devices.[45] The exposure routes and forms are very different in these cases, and, for 
example, a manufacturer designing a silver NM for use in printing would not typically want to 
generate risk assessments that should be applied for the case of direct contact with wounds. Use is 
intimately connected with the resulting exposure route. While exposure has been evaluated less as a 
key criterion for evaluating the risk of NMs[46] it may therefore be practical to continue to regulate 
NMs based on their functional use (therefore exposure), as has been done, to a limited extent, for 
nanosilver in the US, which is regulated under the regulations for pesticides. This functional use 
grouping, would bring all materials registered for a given use (nano and non-nano) together rather 
than attempting to bring all nano-scale materials under a single regulatory umbrella. Such a use-
based approach could possibly be more efficient but should also be framed more by socio-ecological 
precautionary considerations rather than the economically focused process we currently see under 
REACH.  
It is worth mentioning that the assessment of realistic exposure levels has also been put in the 
centre of the Next Generation Risk Assessment (NGRA) approach – a step beyond the classic risk 
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critical doses obtained from animal studies, e.g., NOAEL by some safety margins, e.g., a factor of 10 
for the extrapolation from the test animal to human, plus an additional 10 to account for variability 
within the human population. NGRA is defined as an exposure-led, hypothesis-driven approach that 
incorporates one or more ‘New Approach Methodologies’ (NAMs, typically alternatives to animal 
testing) to ensure that the chemical does not cause harm to consumers. This requires development 
of integrated, tiered and iterative strategies that integrate various types of experimental studies, 
such as high-throughput studies (HTS) and omics analyses with computational techniques, such as 
quantitative structure-activity relationships (QSAR), threshold of toxicological concern approach 
(TCC), quantitative in vitro-in vivo extrapolation (QIVIVE), physiological-based pharmaco-kinetics 
modeling (PBPK) and read-across.[47]–[49] 
As mentioned above, the revised Annex VI of REACH[50] introduced the concept of nanoform into the 
Regulation, which addresses the information requirements concerning nanoscale variants of 
chemical substances, such as NMs. The introduction represents an increase in requirements for the 
authorisation and possibility to commercialise NMs and products containing them. Within the 
REACH Regulation, NMs are considered as special forms of a chemical substance, whereas the term 
nanoform is used to distinguish different NMs forms, e.g., different sizes, shapes or coatings, of the 
same registered substance.[51], [52] Consequently, each nanoform of a particular substance must be 
identified and characterised in the registration dossiers. A nanoform must be characterised in 
accordance with Annex VI section 2.4 of REACH, which states that a substance may comprise of one 
or more different nanoforms, depending on the differences in several particle parameters, which 
always have to be considered jointly, i.e., i) size distribution; ii) shape and other morphological 
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least one of the above parameters will result in a different nanoform, unless it is a result of batch-to-
batch variability. Since different nanoforms of a particular NM may differ significantly in terms of 
their physical, chemical and/or morphological properties, it is expected that different nanoforms of 
the same substance (same NM) may also differ in terms of causing adverse effects on human health 
and/or the environment, and thus require separate assessment unless they can be demonstrated to 
constitute a set of nanoforms of similar behaviour. 
Given the ongoing uncertainty to which physico-chemical characteristics of NMs correlate with 
toxicity,[53], [54] a risk governance approach has been suggested in order to develop collaborative 
mechanisms across multiple stakeholders and institutions to craft and implement the standards, 
best practices, and operating culture within the nanotechnology industry.[17] Such an approach may 
benefit from the operationalisation of the Safe(r)-by-Design (SbD) concept that is a growing 
requirement within individual governments, but would also stimulate innovation in the international 
landscape of emerging technologies.[55] 
The SbD concept aims to establish selection rules and synthetic approaches that can be used for the 
reduction of associated risks, while considering the life cycle of products in order to protect workers, 
users and consumers.[56] This can be achieved by reducing NMs hazard and/or exposure, reducing 
the migration and/or release of NMs and the controlled degradation once released from their 
matrices.[31], [56] The implementation of SbD approaches is one of the main elements of risk 
governance of nanotechnology and its incorporation into the risk governance framework can enable 
timely and effective high-tech innovation, making NM-products safer for humans and the 








3. Moving from risk assessment and management to governance of nanomaterials and 
nanotechnologies 
It is well established by most stakeholders in the nanotechnology field, i.e., scientific community, 
regulators/policy makers and industry, that traditional risk assessment/risk management, although 
broadly applicable for NMs, demands a high level of adaptation and optimisation. This is mainly due 
to: i) the special features of NMs, including their aforementioned applications in a wide array of 
consumer and industrial applications; ii) their enormous diversity of properties; iii) their dynamic 
nature that responds to / is determined by their surroundings (sometimes called extrinsic 
properties);[31], [58], [59] and iv) the extensive gaps in their characterisation under relevant exposure 
conditions and timescales.[60], [61] Primary research efforts have so far focused on adjusting risk 
assessment and management frameworks for chemicals to account for the properties and 
characteristics of NMs.  
The complexity of the topic and the need for a holistic approach have led to the shift in focus from 
simpler processes of risk assessment to risk governance of NMs, seeking more relevant rules, 
validation procedures and regulatory accepted processes within risk governance.[14] These processes 
aim to cover the whole innovation process along the life cycle of a specific NM, thereby allowing a 
deeper analysis of foreseeable risks that may be posed by NMs, nano-enabled products and 
processes. 
Scott-Fordsmand et al.[14] have analysed the current state of the art in the nanosafety sector, by 
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nanoinformatics tools, operational tools, governance framework, governance council. In the same 
study, the current status and what is missing have been analysed, while a way forward is proposed 
for each of the sub-sectors, followed by a general roadmap and a view into the global perspective of 
nanosafety. A key recommendation from that work was the urgent need for the development of a 
holistic risk governance framework, whose aim is to integrate scientific data and operational tools, 
which coupled with guidance and test guidelines can lead to the operationalisation of a Risk 
Governance Council. 
Key gaps that have been identified include the ongoing lack of: i) consensus in a risk management 
framework for NMs; ii) certified reference materials and positive/negative controls for NMs; iii) 
official test guidelines for characterization and toxicity evaluation; iv) methodologies for 
understanding of the social impacts of nanotechnologies; v) consensus strategies for the transfer of 
acceptable risk arising from NMs; and vi) proper communication towards stakeholders and society. 
To address these gaps, the RiskGONE consortium envisages a pragmatic approach, based on the 
latest developments in the risk governance sector, which will be translated into web-based and 
flexible, yet tailored, guidance schemes to support the governance of the risks during the innovation 
process of NMs. 
Inspired by initial discussions on risk governance of nanotechnology in the mid-2000s, scholars are 
now debating how and to what extent it may be developed and implemented within various 
jurisdictions or industries. For example, Hristozov et al.[62] have detailed the range of different risk 
pre-assessment and evaluation methods available, Lombi et al.[63] addressed risk governance in the 
agriculture-nanotechnology field, while Grieger et al.[64] have detailed the bevy of tools for risk 
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nanotechnology risk communication and mitigation, Trump et al.[67] presented six options that have 
been deployed to address uncertainty regarding NMs in the United States, the European Union, as 
well as in developing countries, while Sørensen et al.[68] evaluated environmental risk assessment 
models for NMs, in relation to their applicability within the caLIBRAte product innovation framework 
for NMs risk governance. 
 
4. Risk governance frameworks for nanomaterials 
During the last decade, several attempts have been made to create a framework tailored to the risk 
governance of NMs. Notable developments include the Nano Risk Framework,[69] the ISO 
31000:2018 Risk Management framework for new technologies,[70] the risk governance framework 
of IRGC for NMs with specific guidelines on governance of emerging risks,[71], [72] the iNTeg-Risk 
project Emerging Risk Management Framework (ERMF)[73] and the frameworks developed by EU 
funded projects such as NanoTEST,[74] MARINA,[75] SUN,[76] NANoReg,[77] NANoReg2,[78] caLIBRAte[79] 
and NanoMILE.[80] Most of these approaches contain similar elements that form the main pillars of 
risk governance for NMs, such as ‘risk pre-assessment’, ‘risk concern/safety assessment’, ‘risk 
evaluation’, ‘risk management and decision making’, while they are complemented by continuous 
supporting processes such as ‘risk communication’ and ‘monitoring’, as identified by Isigonis et al.[66] 
The most important characteristics of these frameworks have been analysed in relation to their 
suitability for risk governance of NMs, their advantages and disadvantages, their acceptability, legal 
basis and broad applicability, enabling identification of knowledge gaps that need to be filled, as 
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A straight-forward methodology has been adopted here for assessment of the relevant existing 
frameworks, by combining elements of gap analysis and SWOT (strengths, weaknesses, 
opportunities and threats) analysis. In the first phase, the frameworks have been analysed to 
distinguish their main advantages and disadvantages, in terms of their suitability for adoption and 
expansion within a general setting for the risk governance of NMs. Advantageous characteristics 
present in the various frameworks have been identified, such as nano specificity, incorporation of 
SbD elements for NMs, wide applicability, presence of guidance, comprehensive applied tools etc. In 
addition, the most important drawbacks of each effort have also been identified, such as the lack of 
guidance, lack of nano specificity and applicability in comprehensive tools, the (over)simplicity of 
some frameworks, the focus on a limited set of risk governance processes etc. The second phase of 
analysis focused on identifying the level of data intensity that is required for the application of each 
framework (e.g. qualitative vs quantitative assessments, low/medium/high data intensity) and 
specific characteristics related to the stakeholder acceptance, in terms of regulatory compliance, and 
the applicability of the frameworks in low and middle income countries. It is worth noting at this 
stage that none of the proposed frameworks has complete regulatory acceptance/adoption so far, 
which together with the legal basis are two rather important characteristics in the effort to establish 
frameworks and standards suitable for risk governance of NMs overall. The last phase of the analysis 
performed herein considered possible improvements and steps that would allow widespread 
acceptability and possible utility of each analysed framework for the RGC. This step identified a 
number of options such as expansion to cover a larger number of risk governance processes, 
integration in web tools or decision support systems, provision of extensive guidance and others. All 
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further utilization within the design of the risk governance framework that is being developed by the 
RiskGONE consortium. 
The proposed framework aims to incorporate valuable existing information and the new 
developments into one structure that will be the basis for the operationalization of the RGC. The 
existing risk governance frameworks have specific drawbacks, as analysed and summarised in Table 
1, and include fragmented resources based on the background and the scope of their development, 
therefore it is considered sensible to collect all the important elements under one umbrella, i.e., 
within the envisioned holistic risk governance framework. 
To support innovation, a strong focus of recent research has been driven towards establishing 
procedures that would allow the integration of SbD concept into NMs development and 
commercialisation at the outset, therefore aiming to couple the risk governance processes with 
regulatory and business needs and embedding risk governance concepts into the underlying 
frameworks.[57], [81]–[83] 
The integration of SbD together with concepts of ‘Quality-by-Design’ and ‘Sustainability-by-Design’ 
for NMs has been envisioned in related frameworks.[84], [85] To achieve such an operationalisation of 
SbD and related concepts, scientific and regulatory needs are mapped in parallel with innovation 
management needs that together with prevention-based and safer-innovation approaches have to 
be incorporated within the emerging risk governance frameworks. Achievement of such a holistic, 
operational and transparent framework, acceptable to and trusted by all stakeholders is the ultimate 
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Despite the undoubted progress in the field, consensus on the safe development and handling of 
nanotechnology among the various stakeholder groups is still considered as a great challenge.[86] 
Therefore, the dedicated Risk Governance Council (RGC) for NMs, under development by three 
H2020-funded research projects (Gov4Nano,[26] NANORIGO[27] and RiskGONE[28]), aims to support the 
translation of research advances into regulation and industrial practice, and to integrate research, 
development and innovation (R&D&I) processes in nanotechnology in a holistic way. These projects 
aim to design and implement a broadly accepted among stakeholders, scientifically-based risk 
governance framework for NMs by filling identified gaps of the existing efforts[14] (see Table 1 above 
for some of the key information gaps identified in terms of broad applicability, stakeholder 
acceptability and legal basis). Furthermore, the projects aim to support the framework through a 
dedicated web platform and allow modular expansion possibilities to accommodate the future 
needs of NMs industries, regulators and the general public. This approach is expected to enable a 
continuous incorporation of the evolving state of the science to facilitates responsive re-thinking of 
nanosafety governance to address these future needs. In addition, in close cooperation with all 
consortia, three H2020-funded research projects (NanoCommons,[87] NanoInformaTIX[88] and 
NanoSolveIT[89]) are developing models which can make predictions based on prior experimental 
inputs, utilising only knowledge of NM structure and composition, enabling NMs developers to 
screen NMs in silico before actually producing them, thus ensuring that the properties of concern 
are reduced or eliminated, which would make the NMs SbD.[90] 
As more experimental data become available, these models can be retrained to be more robust and 
extend their domain of applicability to gain more insight into the features driving NMs functionalities 








5. A scientific view on a universal risk governance framework and plans for development and 
operationalisation of a Risk Governance Council 
Responsible and sustainable nanotechnology innovation requires the development and 
implementation of widely agreed strategies and tools for prevention, assessment, communication 
and management of risks and impacts, across materials and product life cycles. It should also reflect 
contiguous concerns, such as the circular economy, critical raw materials, the water and waste 
framework directives[91], [92] and guidance in food and feed chains,[93]  ultimately leading to the 
development of a holistic risk governance framework for nanotechnologies and NMs.[14] Within the 
RiskGONE project, a modular risk governance framework is envisioned, based on the state-of-the-art 
in the nanotechnology sector, the incorporation of risk/benefit ratio and ethical assessments[94] and 
the efforts to couple the notions of life cycle thinking, prevention-based risk governance, SbD, safe 
innovation governance, contiguous frameworks and open data initiatives with the existing four main 
pillars of the risk governance process, as shown in Figure 1. 
The principal components of risk governance frameworks, such as risk pre-assessment, risk 
appraisal, risk evaluation and risk management have been described extensively in various previous 
studies.[66], [71] They are accepted by the scientific community as important steps in chemical and 
material assessment and are used in the most recent research regarding risk governance processes 
for NMs. Our study uses the pre-existing principal components as the basis of the envisioned risk 
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are currently missing and are considered essential towards the establishment of science-based risk 
governance of NMs, as also seen in Table 1. These elements include the following: 
 Promotion of the incorporation of the SbD concept, alongside the Sustainability by design 
and Quality by Design concepts, within assessment frameworks and their operationalisation 
through comprehensive tools, which are currently in their infancy or missing completely. 
This effort is meant both to help innovation governance, to support responsible research 
and innovation with practical and operational tools and to enhance predictive actions and 
measures covering the life cycle of NMs or even precede their realization via in silico 
screening.  
 Communication among stakeholders through bi-directional communication tools; a web-
based platform which will allow the public to communicate with stakeholders and vice versa, 
in an effort to facilitate dialogue and explore public and societal objectives. 
 Guidance and standardization documents, for enhancing the regulatory compliance and 
acceptance of the developed framework and the incorporated tools. 
 Strengthening of the scientific efforts towards open data and global data availability, 
through the development of open databases and repositories supporting FAIR data and 
promoting the FAIRification processes. 
 Utilization of risk governance tools (both existing and those to be developed) and 
incorporation of decision trees that will guide the users (covering regulators, industry and 
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to available resources for the needs of each stakeholder group. Resources will include 
guidance documents, standardization documents, public summaries, internet resources 
(databases, information portals), communication tools and scientific tools. 
The Risk Governance Council is at the epicentre of all the developments of the RiskGONE project, 
therefore closely related to the development of the risk governance framework and the associated 
supporting infrastructure, i.e., data, tools & instruments, that is expected to be developed until the 
end of project timeframe. The RGC is expected to undertake and optimize multiple stakeholder 
involvement activities through the bidirectional communication channel that is under development. 
The risk governance frameworks developed so far have not been designed with exclusive 
consideration of how they would be operationalised, i.e., outlining how the framework would 
support the work of a science-based, regulatory, sustainable RGC, that would be able to provide 
expert opinions on the ongoing developments in risk related issues for NMs tailored to the needs of 
regulators, industry, society and other stakeholders. The foundation of the RGC’s activities, based on 
the RiskGONE consortium vision, should be based on various key steps for creating a strong formal 
framework: i) using FAIR (Findable, Accessible, Interoperable and Reusable[95]) scientific data; ii) 
making use of OECD / EURL ECVAM (European Union Reference Laboratory for alternatives to animal 
testing / European Centre for the Validation of Alternative Methods) validated datasets and 
nanoinformatics tools; iii) enabling the operationality of the tools for aligning the risk governance 
practices through accessible cloud platforms; and iv) aligning with open data initiatives and 
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The vision is thus to design a framework for supporting the RGC activities through the early adoption 
of scientific advances and emerging data and their translation via functional tools, all within a 
transparent, guided decision scheme considering the needs and expectations of the various 
stakeholders. The risk governance framework will be available as an interoperable cloud platform 
with a user-friendly interface and operationalised via a set of decision trees implemented into a 
modular decision support tool providing instruments, guidance and guidelines for different aspects 
of the risk governance of NMs, such as: 
 Characterisation, Fate, and Dosimetry of NMs  
 Human Hazard Assessment  
 Environmental Hazard/Effect Assessment  
 Exposure Assessment 
 Human Health Risk Assessment  
 Ecological Risk Assessment 
 Environmental Impact Assessment and Life Cycle Analysis 
 Social Impact Assessment and Risk-benefit analysis 
 Economic Assessment 
 Risk Reduction 
 Risk Transfer  
 Risk Communication 
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Tools are expected to be categorized based on their suitability for use in the different risk 
governance processes and their reliability to support them. Specific assessment has been done in 
previous projects, such as within the H2020 caLIBRAte[79] project where the evaluation of the 
relevance of tools for horizon scanning, environmental risk assessment and human health risk 
assessment has been performed. These results will be complemented with new tools, especially 
those developed within the NanoSolveIT, NanoCommons and NanoInformaTIX nanoinformatics 
projects.[87]–[89] Multiple tools covering the multiple stages of risk governance processes therefore 
they are expected to be proposed to the users in the various modular yet integrated segments of the 
decision trees that will be used to guide the users to appropriate resources.[66] 
The specific system requirements and specifications are currently being defined in collaboration with 
the NanoSolveIT project. Concrete exploitation and sustainability plans are also foreseen and are 
currently under development to ensure continuity, beyond the specific project duration.  Key 
aspects of the cloud platform include the utilisation of open access approaches where feasible, 
recognition of the need for data security, the need for easily extendable and adaptable approaches 
to keep pace with knowledge and technological development, and its hand-over to the RGC, in any 
of the possible forms it might take, as part of the long term operationalisation. Project partners 
commit to keeping the cloud platform functional for at least 5 years beyond the project lifetime in 
the absence of its uptake and onward development by the RGC. 
The decision trees will be designed and implemented, to provide scientific and regulatory support 
via reinforced decision-making tools and facilitated risk communication to relevant stakeholders, 
including industry, regulators, insurance companies, NGOs and the general public. The decision trees 
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governance processes. The required, critical properties of nanoforms would be predicted 
(calculated) with the implemented nanoinformatics tools that are currently under development by 
the collaborating projects (NanoSolveIT, NanoCommons and NanoInformaTIX). The framework is 
expected to support regulatory decision-making as well as business management needs, through the 
adoption of best practices, the promotion of Responsible Research and Innovation (RRI)[96]–[98] and 
the exploration of frameworks for Responsible Innovation[99] for integration with the proposed risk 
governance framework to align policy-making with research practices. Extension to other relevant 
advanced materials and emerging technologies is also envisaged along with leveraging of best 
practice from contiguous disciplines. 
In some respects, the results of almost 20 years of risk research have shown that health hazards 
from respirable, bio-resistant dusts in particle and fibrous form are not limited to diameters below 
100 nanometres, but also affect other (advanced) materials that do not fall under the definition of a 
"nanoform".[100]–[102] Recent debates consider NMs as new materials generally, where the nanoscale 
is one feature, but not the only one. To address the size issue, it is indicated that particulate 
behaviour, irrespective of whether engineered or incidental, is clearly correlated with disease 
outcomes in specific cases.[103] Even though understanding the subtleties of these features, 
especially their potent combinations, is advancing, further research is needed. A library of NMs has 
been recently published,[104] which contains information that is clearly above what can be measured 
case-by-case and would allow determination of groups of nanoforms, once appropriate models are 
developed and validated for regulatory use. However, specific investment through governance / 
stakeholder dialogue is needed to determine what are the appropriate endpoints for screening 
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very little is still known about chronic and multi-generational effects. Thus, significant research 
investment is still needed to address these aspects of NMs safety and support revision of test 
guidelines for NMs.[105], [106] A long-term aim of the Risk Governance Council must thus include 
continuous monitoring, investigation and understanding of NMs behaviour and risks, i.e., – in one 
word, governance. This issue contributes to the change of focus in the next EU research framework 
programme "Horizon Europe", where the corresponding funding for risk research is anchored under 
the generic term "advanced materials". Considerable uncertainty still exists, thus making NMs an 
example of the diversity and complexity of advanced materials. 
The operationalisation of the risk governance framework remains a great challenge, as previous 
efforts were mainly conceptual, lacked regulatory acceptance and were barely used for decision 
making, or to support solving practical problems or clarification of concerns and uncertainties in the 
nanosafety sector. Now driven directly by regulators, the establishment of a risk governance body 
for NMs will enable the RGC to make developed tools operational and to provide communication 
with stakeholders and civil society, based on high quality information, by reviewing scientific and 
regulatory data to provide science-based, justified opinions regarding the environment and human 
health safety of NMs applied in different products and sectors. The following characteristics are 
considered vital for establishing the functionality of the RGC and its development should ensure: 
 Financial stability/sustainability 
 Neutral / independent status and reputation 
 Transparent and science-based procedures and advice 









The challenge posed in the nanotechnology sector is the development of a universally-accepted 
framework, which is able to meet the risk and innovation governance challenges that are known at 
the moment, while at the same time is flexible enough to accommodate the envisioned needs of 
nanotechnology and advanced materials as an emerging technology. Operationalisation and 
obtaining regulatory acceptance of the framework remain key open questions, which should be 
tackled in parallel with its development, while tackling the uncertainty and diversity / complexity of 
NMs is considered also a top priority. Consensus is vital for the success of the RGC and thus strong 
focus is needed to perform effective collaboration among the three risk governance (Gov4Nano, 
NanoRIGO and RiskGONE) and the three nanoinformatics projects (NanoCommons, NanoSolveIT and 
NanoInformaTIX), that are developing the models and predictive tools that the RGC will use once 
established. Such collaboration and coordination of efforts, should consider existing methods, 
together with cross-validation of new models / modelling approaches, including their predictive 
power and applicability domains, to enable achievement of the collective goal of reaching 
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Figure 1. Schematic illustration of the holistic and implementable RiskGONE universal 










Table 1. Characteristics of risk governance frameworks developed or adapted for NMs during the 
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